| Tiffany R Vannatta, | |
|
800 Main St Ste 204, Anderson, IN 46016-1545 | |
| (765) 644-0500 | |
| (765) 644-0510 |
| Full Name | Tiffany R Vannatta |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 800 Main St Ste 204, Anderson, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548602527 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 22004994A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tiffany R Vannatta, 800 Main St Ste 204, Anderson, IN 46016-1545 Ph: (765) 644-0500 | Tiffany R Vannatta, 800 Main St Ste 204, Anderson, IN 46016-1545 Ph: (765) 644-0500 |
News Archive
Canada Health Infoway (Infoway) and Agfa HealthCare, a leading provider of diagnostic imaging solutions, have reached a Preferred Solution Agreement (PSA) providing preferential conditions and pricing for Agfa HealthCare's IMPAX(TM) 6 Picture Archiving and Communication System (PACS) and Viewer as well as its IMPAX(TM) Data Center and Diagnostic Imaging Repository (DI-r). This is the second time Infoway and Agfa HealthCare have achieved a Preferred Solution Agreement.
Reuters and The Wall Street Journal challenge the notion, based on recent jobs data, that the health law is causing an erosion of full-time work. Other media outlets look at the endangered status of new insurance co-ops funded by the law, the high price of many prescription drugs and concerns about the people enrolled in high-risk insurance pools that will close at the end of the year.
TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a Phase 1 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder and urge urinary incontinence.
Trius Therapeutics, Inc. announced that on February 26th, 2010, the FDA issued new draft guidance on non-inferiority clinical trials that will apply to the design of the Company's proposed Phase 3 trials for its investigational antibacterial drug torezolid phosphate.
› Verified 8 days ago
Mrs. Valerie Jill Robertson, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2311 Cedar Bnd, Anderson, IN 46011 Phone: 765-621-1593 | |
Michelle Rose, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 800 Main St Ste 204, Anderson, IN 46016 Phone: 765-644-0500 Fax: 765-644-0510 | |
Mrs. Lindsey Ann-marie Zurawski, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1345 N Madison Ave, Anderson, IN 46011 Phone: 765-644-2888 Fax: 765-683-4372 | |
Stephanie Ketring, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 800 Main St Ste 204, Anderson, IN 46016 Phone: 765-644-0500 | |
Ms. Gina Pease Russel, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4610 Madison Ave, Anderson, IN 46013 Phone: 765-641-2037 Fax: 765-641-2041 | |
Mrs. Susan Michelle Lee, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1827 N Madison Ave Ste B, Anderson, IN 46011 Phone: 765-313-7570 Fax: 844-364-1385 | |
Lora Repp, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5325 Main St, Anderson, IN 46013 Phone: 765-642-0201 |